Clinical practice guideline (CPG), clinical practice algorithm (CPA), and clinical checklist (CC, collectively CPGAC) development is a high priority of the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE).

Osteoporosis is a growing major public health problem with impacts on quality and quantity of life that cross medical, social, and economic lines. These guidelines were developed by the American Association of Clinical Endocrinologists (AACE) with hopes of reducing the risk of osteoporosis-related fractures and thereby maintaining the quality of life for people with osteoporosis.

This consensus document will present recommendations for the use of MHT for the relief of menopausal symptoms. It will consider the possible role of MHT in the prevention of chronic disorders associated with estrogen deficiency. Moreover, it will assess the benefit-versus-risk profile of MHT, including our current understanding of the effects of MHT on multiple organ systems.

The purpose of these guidelines is to present a framework for the evaluation, treatment, and follow-up of the patient—indeed, of the couple—who presents with sexual dysfunction. The conventional focus on male erectile dysfunction is incomplete because whenever a man experiences erectile difficulties, his wife or sexual partner suffers as well.

In these clinical practice guidelines, specific recommendations are made for determining the most effective methods of diagnosing and treating hypogonadism in adult male patients.

The purpose of this document is to provide guidelines for the diagnosis and treatment of hyperandrogenic disorders in women. These may range from simple hirsutism, without clearly demonstrable biochemical features of hyperandrogenism, to frank virilization.